Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04536688 · ClinicalTrials.gov registry record · Phase 1
A Study of RGLS4326 in Patients With Autosomal Dominant Polycystic Kidney Disease
A Phase 1 study, sponsored by Regulus Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 19
- Enrollment target
NCT04536688 is a Phase 1 study that has completed, run by Regulus Therapeutics. The registered enrollment target is 19 participants.
The verdict
NCT04536688, a Phase 1 study, has completed, sponsored by Regulus Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 19 participants
- Enrollment target
Study Summary
Primary Objective • To assess the dose response relationship between RGLS4326 and ADPKD biomarkers Secondary Objectives * To characterize the pharmacokinetic (PK) properties of RGLS4326 in plasma and urine * To assess the safety and tolerability of RGLS4326
Interventions
- DRUG RGLS4326
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2020-10-13 |
| Est. Completion | 2021-11-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04536688
The ClinicalTrials.gov registry entry for NCT04536688 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 19 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Regulus Therapeutics, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which RGLS4326 is the first listed.
NCT04536688 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04536688 about?
NCT04536688 is a clinical study titled "A Study of RGLS4326 in Patients With Autosomal Dominant Polycystic Kidney Disease". Primary Objective • To assess the dose response relationship between RGLS4326 and ADPKD biomarkers Secondary Objectives * To characterize the pharmacokinetic (PK) properties of RGLS4326 in plasma and urine * To assess the safety and tolerability of RGLS4326
What is the current status of trial NCT04536688?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 19 participants. The study started on 2020-10-13. Estimated completion is 2021-11-12.
What interventions are being tested in trial NCT04536688?
The interventions under investigation include: RGLS4326 (DRUG).
Who is sponsoring clinical trial NCT04536688?
This trial is sponsored by Regulus Therapeutics, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.